ZWZachary Scott Wallace

Zachary Scott Wallace

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zachary Scott Wallace has a total of 546 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoqing Fu

    Rheumatology and Allergy Clinical Epidemiology Research Center, Mongan Institute, Massachusetts General Hospital, Boston, MA, USA; Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

    36 shared publications
  • Jeffrey Andrew Sparks

    Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

    30 shared publications
  • Claire Cook

    Rheumatology and Allergy Clinical Epidemiology Research Center, MGH, Boston, Massachusetts, USA

    22 shared publications
  • John H. Stone

    Massachusetts General Hospital, Boston, MA, USA

    18 shared publications
  • Hyon K. Choi

    Massachusetts General Hospital, Harvard Medical School Boston MA

    17 shared publications
  • Yuqing Zhang

    Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital , Boston, MA, USA

    16 shared publications

Latest Publications

  • Open Access

    B‐Cell Depletion Relative to Tumor Necrosis Factor Inhibition Extends the Duration of Viral Shedding in COVID‐19 Among Autoimmune Disease Patients: A Matched Prospective Cohort Study

    by Liya Sisay Getachew, Xiaosong Wang, Naomi J. Patel, Zachary S. Wallace, Lauren A. O'KEeffe, Madison Negron, Jiaqi Wang, Grace Qian, Alene A. Saavedra, Kevin T. Mueller, et al.

    Objective: To investigate SARS‐CoV‐2 viral shedding duration in autoimmune patients using B cell depleting (BCD) therapy or tumor necrosis factor inhibitors (TNFi) and immunocompetent comparators. Methods: We conducted a matched cohort analysis among participants in POSITIVES, a prospective study enrolling outpatients with acute COVID‐19 within five days of diagnosis. Anterior nasal swabs were self‐collected thrice weekly over two weeks and then weekly until two negative polymerase chain reaction (PCR) results. We compared autoimmune cases on BCD or TNFi at baseline with immunocompetent comparators, matched using a propensity score based on age, sex, race and ethnicity, number of COVID‐19 vaccinations, calendar time, and antiviral use. Survival methods with Cox proportional hazards modeling was used to compare the time to undetectable PCR. Results: We enrolled 16 BCD users and 30 TNFi users, each matched to 33 and 53 immunocompetent comparators, respectively. The most common autoimmune disease was rheumatoid arthritis (31% among BCD and 53% among TNFi). About 60% used an antiviral, and the mean number of COVID‐19 vaccinations was 4.3. At the time of infection, BCD users had significantly longer viral shedding duration than comparators (median 15 vs 7 days; hazard ratio [HR] 0.43, 95% confidence interval [CI] 0.22–0.86; P = 0.017). The median time to undetectable viral load was similar between TNFi users and comparators (10 vs 8 days; HR 0.77, 95% CI 0.48–1.23; P = 0.27). Conclusion: BCD users had eight days longer viral shedding duration than immunocompetent comparators; TNFi users and comparators had similar viral shedding duration. These findings inform clinical and public health strategies for autoimmune patients with COVID‐19. image

  • Open Access

    Real-World Effectiveness and Safety of Avacopan in ANCA-Associated Vasculitis: A Systematic Literature Review and Meta-analysis

    by Elizabeth Ibiloye, Niranjan Kathe, Kelsey Mirkovic, Coby Martin, Siyu Tu, Rachel Gamburg, Jatinder Kumar, Goutam Solanki, Zachary S. Wallace

    Background: The efficacy and safety of avacopan in ANCA-associated vasculitis (AAV) has been established in randomized trials of of avacopan as a glucocorticoid (GC)-sparing therapy. However, real-world evidence (RWE) has an important role in confirming effectiveness and evaluating safety in more generalizable settings. This study aimed to synthesize RWE on the effectiveness and safety of avacopan in adults with AAV. Methods: A systematic literature review and meta-analysis of non-interventional real-world studies was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) guidelines. Eligible studies included adults with AAV treated with avacopan in routine clinical practice. Pooled estimates of effectiveness and safety outcomes were calculated using random-effects meta-analyses. Primary outcomes included remission at 6 and 12 months and sustained remission at 12 months. Secondary outcomes included relapse, GC use and dosing, hepatotoxicity, infections, and treatment discontinuation. Exploratory outcomes included changes in estimated glomerular filtration rate (eGFR) and dialysis-related endpoints. Results: A total of 71 studies were included and contributed to quantitative analyses. Pooled remission for patients on avacopan was 87% (95% CI: 75%-94%) at 6 months and 93% (95% CI: 86%-97%) at 12 months, and sustained remission was 86% (95% CI: 74%-93%) at 12 months. Relapse at 12 months was low (7%; 95% CI: 4%-11%). GC use was 36% at both 6 and 12 months. Improvements in eGFR were observed at 6 months (18 mL/min/1.73 m²) and 12 months (18 mL/min/1.73 m²), and dialysis liberation was 66% in a limited subset. Among avacopan patients, 11% experienced any hepatotoxicity, including 7% with serious (defined as directly reported or requiring hospitalization) hepatotoxicity, while 7% experienced serious (defined as directly reported or requiring hospitalization) infection. Conclusions: In real-world clinical practice, avacopan is associated with high remission rates, low relapse rates, and a consistent GC-sparing effect, with effectiveness comparable to standard-of-care regimens. Findings support its clinical use with appropriate safety monitoring; however, the observed heterogeneity in hepatotoxicity and the limited comparative effectiveness evidence highlight areas requiring further investigation.


  • Open Access

    Real-world clinical and economic burden of immunoglobulin-G4-related disease in the United States: A retrospective claims-based analysis

    by Zachary S. Md Wallace, Jenny Y. Park, Elizabeth MScPH Serra, Patrick Gagnon-Sanschagrin, Annie Guérin, Kristina R. Patterson, Haridarshan Patel, Vikesh K. Md Singh

    Immunoglobulin-G4-related disease (IgG4-RD) is a rare recurring fibroinflammatory autoimmune condition that can affect multiple organs. Although it is gaining recognition, few studies have assessed the clinical and economic burden of this disease. This study aimed to characterize patients with IgG4-RD in the United States and describe healthcare resource utilization (HRU) and costs before and after diagnosis. This retrospective cohort study used a validated algorithm to identify commercially insured adult patients with IgG4-RD from health plan claims data obtained from the IQVIA PharMetrics Plus database (January 1, 2011, to June 30, 2022). The index date was defined as the date of the first observed IgG4-RD-related diagnosis. The baseline and study periods were defined as the 12 months before and after diagnosis, respectively. Demographic characteristics were reported on the index date. Clinical characteristics, IgG4-RD-related treatments, and all-cause HRU and healthcare costs (2022 US dollars, payer’s perspective) were reported during the baseline and study periods. A total of 295 patients with IgG4-RD were included in the study. Comorbid burden was substantial, with hypertension (31.5%), hyperlipidemia (22.4%), and type 2 diabetes (17.3%) being the most common comorbidities after diagnosis. Most patients received IgG4-RD-related treatment before (60.3%) and after (87.8%) diagnosis, with prednisone being the most common (71.5% after diagnosis). Pancreatic and biliary involvement each occurred in nearly a third of patients. Annual HRU was high before (mean of 30.4 outpatient [OP] visits; 22.7% with ≥1 inpatient [IP] admission, lasting a mean of 9.0 days) and after diagnosis (mean of 40.7 OP visits; 35.3% with ≥1 IP admission, lasting a mean of 10.6 days). Mean annual healthcare costs were 1.5 times higher after diagnosis ($69,753) than before diagnosis ($45,844), predominantly driven by increased OP and IP costs. Patients with IgG4-RD had a substantial clinical and economic burden, including high rates of glucocorticoid use, HRU, and healthcare costs both before and after diagnosis. This may suggest a need for earlier detection and improved management of this complex condition. This study provides important insights into the high clinical and economic burden observed in IgG4-RD. Future studies are warranted to gain a deeper understanding of the possible impact of management strategies on patient outcomes.

  • Open Access

    Burden of Metabolic Bone Disease in Patients with Immunoglobulin G4-Related Disease With and Without Autoimmune Pancreatitis: A Cross-Sectional Study

    by Guy Katz, Aubree E. McMahon, Grace A. McMahon, Isha Jha, Marcy B. Bolster, Bohang Jiang, Yuqing Zhang, Ana D. Fernandes, Zachary S. Wallace, Cory A. Perugino, et al.

    INTRODUCTION: Patients with immunoglobulin G4-related disease (IgG4-RD) have risk factors of metabolic bone disease (MBD), yet data are lacking on the prevalence of MBD in IgG4-RD. We assessed screening frequency and prevalence of MBD in patients with IgG4-RD with and without pancreatic involvement. METHODS: Using an IgG4-RD registry, we extracted details from medical records related to MBD in patients who actively followed in our system. Living patients with contact information available were invited to complete surveys detailing MBD and associated characteristics. RESULTS: Seventy patients met criteria for medical records review (n = 17 with pancreatic involvement). Fifty-one percent had taken proton-pump inhibitors, and 30% had investigator-determined MBD. Compared with the US population, the age-standardized prevalence of osteoporosis in the IgG4-RD cohort was higher among both female patients (28.1% vs 19.6%, P = 0.40) and male patients (8.3% vs 4.4%, P = 0.48), though this did not achieve statistical significance. Mean T-scores at all sites were numerically lower in patients with pancreatic involvement than those without (all P > 0.1). In patient-reported data (n = 105), despite 62% of patients reporting ≥3 months of glucocorticoid exposure, only 36% had a dual-energy x-ray absorptiometry performed. Of 15 patients for whom pharmacologic MBD treatment was recommended, 8 (53%) reported adherence to this recommendation. DISCUSSION: The burden of MBD and its risk factors is high in patients with IgG4-RD, yet screening and treatment is low. Although our study was underpowered to detect statistical differences, there may be a greater burden of MBD in patients with pancreatic involvement. Screening and treatment of MBD should be emphasized in these patients.

  • Open Access

    Cross-Neutralization of Distant Coronaviruses Strongly Correlates with Spike S2-Specific Antibodies from Immunocompetent and Immunocompromised Vaccinated SARS-CoV-2-Infected Patients

    by Sara V. Patel, Brooke M. Leeman, Patricia J. Botros, Joanna Folta, Dhiman Shahid, Anya I. Rocque, Andrew S. Joyal, Joseph A. Vecchio, Eliza Passell, Dessie Tien, et al.

    Background/Objectives: Despite the lifting of the COVID-19 public health emergency, SARS-CoV-2 infections continue to be recorded worldwide. The continued prevalence of infection has been attributed to the ability of the virus to evade host immune responses, including neutralizing antibody-derived immunity. The vast majority of antibody escape mutations has been associated with the S1 subunit of the spike protein. The other region of the spike, the S2 subunit, is the most conserved region amongst coronaviruses. We hypothesized that S2-specific antibody levels are modest in vaccinated and SARS-CoV-2-infected patients, resulting in suboptimal neutralization of distant coronaviruses. Methods: Here, we analyzed S1- and S2-specific antibody levels in SARS-CoV-2-infected individuals, including a mixed cohort of those with and without immunosuppression and prior vaccination. Results: We found that S2-specific antibody responses were generally lower than S1-specific antibody responses. Intriguingly, Omicron-S1-specific antibody levels were higher than Wuhan-S1-specific antibody levels despite all vaccinated participants having received Wuhan-spike-based immunogens. This emphasizes the importance of the infecting variant and vaccine immunogen in the production of spike-targeting antibodies and associated hybrid immunity. Although S1-specific antibody levels were generally higher than their S2-specific counterparts, the correlation between neutralization and binding antibody levels was mostly higher in S2- compared with S1-specific responses. Conclusions: We conclude that S2-based immunogens are suitable for the induction of antibody-based immunity against novel SARS-CoV-2 variants but also against more distant coronaviruses, which would support a better protection for the immunocompromised as well as other vulnerable populations.


  • Open Access

    Burden of Glucocorticoid Use and Risk of Toxicities Among Patients with Immunoglobulin-G4-Related Disease: A Retrospective US-Based Claims Study

    by Zachary S. Wallace, Jenny Y. Park, Elizabeth Serra, Patrick Gagnon-Sanschagrin, Annie Guérin, Kristina Patterson, Haridarshan Patel, Vikesh K. Singh

    Introduction Glucocorticoids are commonly used to treat immunoglobulin G4-related disease (IgG4-RD), but there is limited real-world evidence describing glucocorticoid-related toxicities in this population. This study assessed glucocorticoid use and toxicities during the first year after diagnosis among patients with IgG4-RD. Methods The IQVIA PharMetrics® Plus database was used to identify adults with IgG4-RD using a validated algorithm. Patients were stratified according to glucocorticoid use during the 12-month study period following the first observed IgG4-RD-related diagnosis (index date): low glucocorticoid use (prednisone equivalent daily dose [PEDD] < 5 mg/day) or high glucocorticoid use (PEDD ≥ 5 mg/day). Incident glucocorticoid-related toxicities were assessed during the study period and incidence was compared between groups using Chi-square tests. Results Among 295 patients with IgG4-RD, 150 (50.8%) had low glucocorticoid use, and 145 (49.2%) had high glucocorticoid use during the study period. In each glucocorticoid group, mean PEDD was highest in the 3 months post-index and subsequently decreased. At 12 months post-index, 24.7% of the low glucocorticoid use group and 60.7% of the high glucocorticoid use group were receiving glucocorticoids. The high glucocorticoid use group had a significantly higher mean (± standard deviation) number of incident glucocorticoid-related toxicities (1.8 ± 1.7 vs. 1.2 ± 1.3) and more frequently had ≥ 3 glucocorticoid-related toxicities (29.0% vs. 13.3%; both p < 0.01) compared to the low glucocorticoid use group. Specifically, cardiovascular- (29.0% vs. 18.7%), gastrointestinal- (29.7% vs. 16.0%), and infection-related (31.0% vs. 17.3%) toxicities were significantly more common in the high glucocorticoid use group than the low glucocorticoid use group (all p < 0.05). Conclusions In this retrospective, claims-based analysis, high glucocorticoid use was seen in half of patients with IgG4-RD during the first year following diagnosis. Patients with high glucocorticoid use experienced significantly more incident glucocorticoid-related toxicities than those with low use during this first year.


  • Identification of an ANCA-associated vasculitis cohort using deep learning and electronic health records

    by Liqin Wang, John Novoa-Laurentiev, Claire Cook, Shruthi Srivatsan, Yining Hua, Jie Yang, Eli Miloslavsky, Hyon K. Choi, Li Zhou, Zachary S. Wallace


  • Open Access

    Burden of coronary artery calcification in ANCA-associated vasculitis

    by Michael Hendrickson, Anushri Parakh, Brittany Weber, Claire Cook, Catherine Ahola, Sandeep Hedgire, Michael Lu, Zachary S. Wallace

    Background: Cardiovascular disease (CVD) is a leading cause of death in ANCA-associated vasculitis (AAV). Screening and primary cardiovascular prevention may improve outcomes. Methods: We identified patients in the 2002–2019 Mass General Brigham AAV cohort with thoracic CT scans obtained for other clinical purposes. Coronary artery calcium (CAC) scores and age, sex and race-standardised CAC percentiles were calculated. Quantile regression was used to identify differences by ANCA type, and Gray’s test examined differences in major adverse cardiac events by CAC score. Results: Of 175 included patients, 127 (73%) were MPO-ANCA+and 48 (27%) were PR3-ANCA+. The median CAC score was 17 (IQR 0, 334) and CAC percentile was 45 (IQR 0, 78); 65 (39%) patients had CAC of ≥100. The total CAC score was higher in patients with MPO-ANCA+AAV vs PR3-ANCA+AAV (median 24 vs 1, p=0.003), as was the standardised CAC percentile (50th vs 34th, p=0.02). Of 116 (66%) patients with non-zero CAC scores, only 29 (25%) were on a statin. In a time-to-event analysis, CAC of 100 or higher trended towards association with higher risk of major adverse cardiovascular events (χ2=1.9, p=0.16). Conclusion: A majority of patients with AAV had clinically significant CAC. There were differences in CAC burden among those with MPO-ANCA+AAV versus PR3-ANCA+AAV. Although CAC is associated with CVD risk and an indication for statins, the use was inconsistent. The role of CT imaging to screen for CVD and guide primary prevention in AAV requires further study.


  • Mechanisms and Screening for Atherosclerosis in Adults With Vasculitis

    by Michael J. Hendrickson, Zachary S. Wallace

    Vascular inflammation is a hallmark of both primary systemic vasculitis and atherosclerosis. As such, cardiovascular events are common in patients with vasculitis and likely due to both direct vascular inflammation and accelerated atherosclerosis. Direct cardiac involvement is possible in all vasculitides, though more commonly described in Takayasu arteritis, polyarteritis nodosa, and eosinophilic granulomatosis with polyangiitis. Accelerated atherosclerosis has been described in Takayasu arteritis and antineutrophil cytoplasmic antibody–associated vasculitis, though there remains a paucity of data in other forms of vasculitis. Multiple screening and management approaches for cardiovascular risk in people with vasculitis have been proposed, though evidence-based guidelines are lacking. In this review, we discuss the latest evidence in epidemiology, mechanisms, and screening for atherosclerosis in patients with primary systemic vasculitides.


  • Kidney Involvement in Pauci-Immune Anti-Neutrophil Cytoplasmic Antibody-Mediated Small-Vessel Vasculitis

    by Madeline Chung, Zachary Wallace, Ashwin R. Shetty, Alana Dasgupta, Salem Almaani, Duvuru Geetha, Anisha B. Dua